BioDelivera, a San Francisco startup in Y Combinator's Fall 2026 batch, says its GCV platform can deliver genetic medicines to tumors, muscle and brain while leaving healthy cells alone. The company's Y Combinator profile provides no experimental data to support the claim, and the whitepaper it links to could not be retrieved for this report.
That gap matters because delivery, getting a genetic payload to the right tissue and nowhere else, is where much of the field's competition now plays out. Large drugmakers have been buying companies that engineer cells inside the body, and any young company promising tissue-specific targeting will be measured against them.
What BioDelivera is claiming
According to its Y Combinator profile, BioDelivera was founded in 2025 and has a team of two. The profile lists the company as active and names Nicolas Dessaigne as its primary YC partner. It is company-provided and carries no publication date, so some details may have shifted.
The profile describes GCV as designed to spare healthy cells and asserts efficacy in tumors, muscle and brain. What it leaves out is considerable: no experimental protocols, no animal species, no dosing, no quantitative biodistribution (the measure of where a therapy actually ends up in the body), no comparator results and no human outcomes.
The company's website links to a whitepaper. Its contents could not be retrieved for this report, and it has not been reviewed. LinkedIn lists the company at 2 to 10 employees, a bracket consistent with YC's figure of two.
The founders and early traction
The venture's earlier footprint is academic. UT Dallas described it as a virus-like-particle cancer-delivery platform in a May 2, 2025 News Center story about its Big Idea Competition. A day later, Retrograde News reported that the team planned to finish their PhDs that summer and raise money by August 2025. Those were stated intentions, and nothing reviewed for this report confirms that either happened.
Who, exactly, is on the founding team is less clear than it should be. AlbPhD Circle and YC describe the team differently. It could not be established whether Durbacz, a name that surfaces in some materials, was an initial co-founder, collaborator, adviser or former team member. A Crunchbase profile for founder Ikeda Trashi has no clear update date, and its employment and degree details remain unconfirmed.
